| VRT |
Report |
Q2 2026 Net Sales |
BEAT |
pred ~$3.44B vs. cons $3.39B |
MEDIUM |
| VRT |
Report |
Q2 2026 Adjusted Operating Margin |
BEAT |
pred ~21.9% vs. cons 21.6% |
MEDIUM |
| VRT |
Report |
Q2 2026 Adjusted Diluted EPS |
BEAT |
pred ~$1.54 vs. cons $1.43 |
HIGH |
| VRT |
Guide |
FY2026 Net Sales guidance |
BETTER |
guide ~$13.95B vs. cons ~$13.85B (FY2026) |
MEDIUM |
| VRT |
Guide |
FY2026 Adjusted Diluted EPS guidance |
BETTER |
guide ~$6.55 vs. cons ~$6.45 (FY2026) |
MEDIUM |
| VRT |
Guide |
FY2026 Adjusted Operating Margin guidance |
BETTER |
guide ~23.6% vs. cons ~23.3% (FY2026) |
MEDIUM |
| VRT |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.0% |
— |
MEDIUM |
| VRT |
Return |
5-day cumulative residual |
+1.0% (FADE) |
Vertiv's track record (Q1'26 beat guide by ~180bps margin/$0.19 EPS; Q4'25 huge beat) argues for another clean beat-and-raise and an initial oversold relief bounce given the stock is down ~28% from May highs and just fell 6.3% in one session on broad 'AI-capex fear' (SK Hynix -47% from highs, Asian tech selloff) unrelated to VRT fundamentals. But precedent shows fades matter: after the Q1'26 beat, VRT's 5-day cumulative idiosyncratic return actually turned negative (~-2 to -4%) despite a strong quarter, as the raise-to-beat ratio underwhelmed elevated expectations and out-quarter growth implicitly decelerated (Street already sits above management's own guide). With EMEA's H2 'coiled spring' recovery still unconfirmed and margin-ramp costs from new capacity a swing factor, any hedge/qualifier on 2H guidance is likely to get discounted by estimate revisions even after a beat, capping day1 gains and pulling the multiple back down over the week as the dominant macro AI-capex overhang reasserts itself. |
MEDIUM |